Clinical Trial: A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07792941) titled 'A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20' on Aug. 25.

Brief Summary: This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Study Start Date: Aug. 27

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: DRUG: tilrekimig and rHuPH20

subcutaneous injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ...